Company Update (NASDAQ:AMGN): Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density . . . → Read More: Company Update (NASDAQ:AMGN): Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels Similar Articles: Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.